Presenter: Dr. P. Usha Rani Resident, ASRAMS, Eluru
Presenter: Dr. P. Usha Rani Resident, ASRAMS, Eluru
Presenter: Dr. P. Usha Rani Resident, ASRAMS, Eluru
Usha Rani
Resident,
ASRAMS, Eluru
Clinical syndrome
characterized by
deficiency of insulin or
insensitivity to insulin
Type Ia- immune mediated beta cell destruction
Type Ib-idiopathic beta cell destruction
Type II-insulin secretory defect with insulin
resistance
Type III-other cause
A-genetic deficiency in beta cell fn
B-genetic deficiency in insulin action
C-ds of exocrine pancreas
D-endocrinopathies
E-drug induced
F-infection
G- Uncommon forms stiff man’s syndrome
Anti - insulin receptor antibody
H- Other genetic syndrome associated with Diabetes Mellitus
Increased Catabolism
Fatigue Hyperglycemia Increased secretion:
Glucagon
Cortisol Wasting
Vulvitis Glycogenolysis
Glycosuria Catecholamines Weight
gluconeogenesis
Growth Hormone loss
lipolysis
Hypoglycemia
Neonatal hypoglycemia is secondary to excessive
insulin production by the neonatal pancreas in
response to maternal hyperglycemia.
Can lead to seizures, coma and brain damage.
Postnatal hyperbilirubinemia
Occurs in appox. 25%, double that of normal.
Due to immaturity of the neonate’s liver function.
Phenobarbital administration antenatally may help
in preventing this condition.
Monitoring
Self monitoring of Bl.Sugar – 4 times/day
Daily urine ketones testing when Bl.Sugar >200mg% or pt is unable to
eat.
ORAL AGENTS
Transplacental passage
Teratogenic
Prolonged hypoglycemia
SECOND GEN. SULFONYL UREA (glyburide) - Does
not cross placenta, achieve satisfactory glucose
control
GLYBURIDE:
Sulfonylurea. Primary mechanism of action is
stimulation of release of insulin from the storage
granules of the pancreatic beta cells.
Also decreases insulin resistance.
Non teratogenic, no noticed fetal effects and effective
control of maternal blood glucose levels are the
reasons for its use in treating GDM.
Side effect: Hypoglycemia.
Dose: 1.25 to 2.5 mg OD or BD. Daily max dose 20 mg.
Peak plasma level: 2-4 hrs. Duration of action: 10-
12hrs
Gold standard
Does not cross placenta
Pt on oral hypoglycemic should be changed to insulin
GDM on diet control will require insulin if fasting
glucose >95mg% or pp>130 mg%
Started with 0.5-0.8 u/kg/day in three divided doses
with regular insulin
Therapeutic objective for plasma glucose level
Fasting 60 – 90 mg/dl
After meal
1 hr < 130 – 140 mg/dl
2hr < 120 mg/dl
1. withhold a.m insulin
2. start glucose infusion– 5% dextrose 125 ml/hr ( 6.25
g glucose/hr)
Begin regular insulin infusion 0.5 U/hr(25 U Iin 250
ml NS)
Monitor glucose every 1 – 2 hr
Adjust insulin infusion
Acute Chronic
DKA Macrovascular
(Atherosclerosis)
Hyperosmolar Coronary
Hyperglycemic non- Cerebrovascular
Peripheral Vascular
ketotic coma (HHNC)
Hypoglycemia Microvascular:
Retinopathy
Nephropathy
Neuropathic:
Autonomic
Peripheral neuropathic
Most common during 2nd and 3rd trimester.
Kussmaul hyperventilation,
signs of volume depletion (e.g., hypotension and
oliguria),
lethargy to coma,
normal-to-cold body temperature and
fruity odour noticeable in the patient’s breath.
Findings for diagnosing DKA:
Bl. Glucose > 250mg/dL.
DKA may develop in pregnancy with bl. Glucose
<250mg/dL and occasionally in the normal range
( EUGLYCEMIC KETOACIDOSIS).
Ketone bodies in urine and plasma.
Arterial pH<7.3
Sr. bicarbonate < 15mEq/L.
Increased anion gap.
It is associated with the following factors:
(1) bacterial infection;
(2) omission of insulin doses in the presence of
gastroenteritis because of the parturient’s concern
about the possibility of an insulin reaction due to
anorexia, nausea, and vomiting;
(3) pump malfunction in patients receiving continuous
subcutaneous insulin infusion therapy and
(4) tocolytic therapy with β- sympathomimetic agents,
with or without concomitant glucocorticoid therapy
(5) decreased caloric intake,
(6) poor medical management,
(7) patient non-compliance.
i.v line
O2 by Face mask
Asses level of glucose& electrolytes
Replacement of fluid
Average fluid deficit 3-5 L
1-2 L in first hr- isotonic N saline followed by
250-500 ml/hr maintenance.
Insulin therapy
The initial insulin dose is a continuous IV insulin infusion using an
infusion pump, at a rate of 0.1 U/kg/h.
A mix of 24 units of regular insulin in 60 mL of isotonic sodium
chloride solution usually is infused at a rate of 15 mL/h (6 U/h)
until the blood glucose level drops to less than 250 mg/dL; the rate
of infusion then decreases to 5-7.5 mL/h (2-3 U/h) until the
ketoacidotic state subsides.
Glucose administration– 5% dextrose(when plasma
glucose reaches 250mg/dL, to prevent hypoglycemia).
Induction –RSI
Difficult intubation trolly
Ketamine not used(hyperglycemia)